CA: A Cancer Journal for Clinicians

This is the number behind almost every statement about how much cancer there is. It shows the burden shifting towards low- and middle-income countries and towards older populations, which is why prevention, screening and affordable treatment in those settings decide the global trend. OnCo's country and prevalence pages draw on the same GLOBOCAN release.

This series is the standard reference for US cancer numbers and the source of most headlines about cancer in younger adults. The gap between falling mortality and rising incidence is the argument for both continued treatment advances and stronger prevention and screening.

The numbers behind the argument that the screening programme is working for the people it covers and failing everyone below its start age; the stage shift going into reverse is the most uncomfortable figure on this roadmap.

This edition supplied two widely quoted signals: the first population-level evidence of HPV vaccination preventing cervical cancer in the United States, and the warning that reduced PSA screening was shifting prostate cancer towards later diagnosis.

This edition documented the treatment-driven fall in lung cancer deaths that followed targeted therapy and immunotherapy, a rare case of new drugs visibly moving national mortality statistics.

One bottleneck page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

This edition documented the fastest ever annual fall in US cancer mortality and attributed it in part to targeted therapy and immunotherapy for lung cancer, one of the clearest links between new drugs and national statistics.

This report marked the shift of the global cancer burden towards breast cancer and towards lower-income countries, and it is the baseline most 2020s policy documents cite. The GLOBOCAN 2022 release has since updated the totals.

One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

This edition is often cited for the disparities finding: progress against cancer in the United States was reaching some communities much more than others.

This was the most cited description of the global cancer burden until the 2020 release and is the reference behind many national cancer plans of the late 2010s. Its country-level comparisons showed where prevention, such as HPV and hepatitis B vaccination and tobacco control, would have the largest effect.

One bottleneck page and 27 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

This edition is widely cited for the early warning about colorectal cancer in younger adults, which later editions confirmed.

Four technology pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

Stage IIB, IIC and III on this site's melanoma pages, and the recognition that stage IIIA has a better prognosis than stage IIB or IIC, come from this system.

One of the most cited editions of the series, used as the reference for US cancer numbers in the mid-2010s.

China accounts for roughly a quarter of the world's cancer cases, and this paper is the reference that made its burden legible internationally. It explains why Chinese trial programmes and drug pipelines concentrate on lung, stomach, oesophageal and liver cancers.

This edition is cited for the shift of cancer to the leading cause of death in a large part of the United States as heart disease mortality fell faster.

This edition marked twenty years of falling US cancer mortality and is cited for the estimate that more than 1.5 million deaths had been averted.

One of the most cited descriptions of the global cancer burden of the 2010s, it framed the shift of cancer towards lower-income countries that later GLOBOCAN releases have confirmed.

Introduced the breakdown of progress by age, race and sex that exposed how unequally the decline in cancer deaths had been shared.

The clearest population-level signature of a targeted drug: the fall in chronic myeloid leukaemia deaths after imatinib.

An early edition of the series that established the now-standard framing of deaths averted since the 1991 peak.

For years the most cited paper in oncology, it fixed the picture of cancer as a growing problem of developing countries and is the baseline against which the 2012, 2018, 2020 and 2022 GLOBOCAN releases show the burden rising.

One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

Confirmed that the decline in incidence and deaths was reaching most population groups, while flagging the groups it was not.

Showed the fall in deaths was concentrated in a handful of common cancers where smoking decline, screening and better treatment had taken hold.

The first edition to express progress as deaths avoided, the framing every later report has kept.

One of the first editions to quantify the sustained fall in US cancer death rates that later reports tracked as deaths averted.

The first of the modern GLOBOCAN summaries in CA, it set the template that Jemal, Torre, Bray and Sung later followed and provides the 2002 baseline for tracking how the global burden has grown and shifted.

The numbers behind the argument that the screening programme is working for the people it covers and failing everyone below its start age; the stage shift going into reverse is the most uncomfortable figure on this roadmap.

One bottleneck page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

One bottleneck page and 27 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

Four technology pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

Stage IIB, IIC and III on this site's melanoma pages, and the recognition that stage IIIA has a better prognosis than stage IIB or IIC, come from this system.

One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.

One technology page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.